In EMBER-3, Inluriyo demonstrated a 38% reduction in the risk of progression or death compared to standard endocrine therapy, with a median PFS of 5.5 vs. 3.8 months. From a clinician’s standpoint, how meaningful is this level of benefit for patients with ESR1-mutated metastatic breast cancer who have progressed on prior endocrine therapy?

Inluriyo binds, blocks, and facilitates degradation of the estrogen receptor, offering continuous ER inhibition in ESR1-mutant tumors. How does this mechanism compare with fulvestrant, and why might oral SERDs represent a new standard of care for endocrine-resistant disease?

Approximately half of patients with ER+, HER2– MBC develop ESR1 mutations after aromatase inhibitor exposure. How has the identification of ESR1 mutations changed your treatment decision-making, and where does Inluriyo best fit in the evolving treatment sequence?

In EMBER-3, 79% of patients had prior exposure to CDK4/6 inhibitors. How do you interpret Inluriyo’s efficacy in this heavily pretreated setting, and what does it suggest about the drug’s potential in earlier lines of therapy?

The trial reported that most adverse events were Grade 1–2, with only 4.6% of patients discontinuing due to side effects. How does this tolerability profile compare with other endocrine therapies, and what should oncologists be aware of regarding the safety monitoring of Inluriyo?

Given that Inluriyo is an oral, once-daily therapy taken on an empty stomach, what are the practical implications for patient adherence and quality of life, especially compared to injectable SERDs like fulvestrant?

With this approval being specific to ESR1-mutated disease, how do you see molecular testing practices evolving? Should ESR1 mutation assessment now become standard at progression for all ER+, HER2– patients?

Inluriyo is also being studied in the Phase 3 EMBER-4 trial for early-stage, high-risk breast cancer. How might positive results in the adjuvant setting further expand the role of SERDs, and what long-term questions remain about durability of benefit and resistance patterns?